Student or educator? Sign up with your school email and get 6 months of Pro free.
CoChat
Sign Up
Cited by 15

The DOI matches its Crossref record; 37 of the 37 references it cites were found in a registry or an index.

Intracerebroventricular anaerobic dopamine in Parkinson’s disease with l-dopa-related complications: a phase 1/2 randomized-controlled trial

Moreau, Caroline, Odou, Pascal, Labreuche, Julien, Demailly, Alexandre, Touzet, Gustavo, Reyns, Nicolas, Gouges, Bastien, Duhamel, Alain, Barthelemy, Christine, Lannoy, Damien, Carta, Natacha, Palas, Benjamin, Vasseur, Michèle, Marchand, Felix, Ollivier, Thomas, Leclercq, Céline, Potey, Camille, Ouk, Thavarak, Baigne, Simon, Dujardin, Kathy, Carton, Louise, Rolland, Anne Sophie, Devedjian, Jean Christophe, Foutel, Véronique, Deplanque, Dominique, Fisichella, Matthieu, Devos, David·2025·Nature Medicine
DOI 10.1038/s41591-024-03428-2

Published version of a preprint

Open this paper in CoChat — free account

Abstract

Continuous compensation for cerebral dopamine deficiency represents an ideal treatment for Parkinson's disease. Dopamine does not cross the digestive and blood-brain barriers and is rapidly oxidized. The new concept is the intracerebroventricular administration of anaerobic dopamine (A-dopamine) using an abdominal pump connected to a subcutaneous catheter implanted in the third ventricle, near the striatum. An open-label phase 1 study showed no serious adverse reactions induced by A-dopamine in 12 patients. A randomized, controlled, open-label, crossover phase 2 study of 1 month of A-dopamine versus 1 month of optimized oral antiparkinsonian therapy was conducted in 9 patients. The primary endpoint, a blinded assessment of the percentage over target (that is, time with dyskinesia or bradykinesia), recorded by home actimetry using a wristwatch, was significantly reduced on A-dopamine compared with that on oral treatment alone (P = 0.027), with a median within-patient difference of -10.4 (Hedge g = -0.62 (95% confidence interval: -1.43, -0.08)). Home diaries were also significantly improved. These initial data on the feasibility, safety and effects of this new device-assisted therapy suggest validation by a large randomized double-blind trial. ClinicalTrials.gov registration: NCT04332276 .

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1038/s41591-024-03428-2

Cites

37 of 37 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 37 references

Metadata

Authors
Moreau, C., Odou, P., Labreuche, J., Demailly, A., Touzet, G., Reyns, N., Gouges, B., Duhamel, A., Barthelemy, C., Lannoy, D., Carta, N., Palas, B., Vasseur, M., Marchand, F., Ollivier, T., Leclercq, C., Potey, C., Ouk, T., Baigne, S., Dujardin, K., Carton, L., Rolland, A. S., Devedjian, J. C., Foutel, V., Deplanque, D., Fisichella, M., & Devos, D.
Venue
Nature Medicine
Publisher
Springer Science and Business Media LLC
Published
2025-01-07
Volume
31
Issue
3
Pages
819-828
ISSN
  • 1078-8956
  • 1546-170X
DOI
10.1038/s41591-024-03428-2
Cited by
15
References
37
Language
en
Licence
Funders
InBrain Pharma

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Intracerebroventricular anaerobic dopamine in Parkinson’s disease with l-dopa-related complications: a phase 1/2 randomized-controlled trial. https://app.cochat.ai/papers/10.1038/s41591-024-03428-2
The paper
Moreau, C., Odou, P., Labreuche, J., Demailly, A., Touzet, G., Reyns, N., Gouges, B., Duhamel, A., Barthelemy, C., Lannoy, D., Carta, N., Palas, B., Vasseur, M., Marchand, F., Ollivier, T., Leclercq, C., Potey, C., Ouk, T., Baigne, S., . . . Devos, D. (2025). Intracerebroventricular anaerobic dopamine in Parkinson’s disease with l-dopa-related complications: a phase 1/2 randomized-controlled trial. Nature Medicine. https://doi.org/10.1038/s41591-024-03428-2

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.